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The development of a vaccine would be essential for the control of schistosomiasis, which is recognized as the most
important human helminth infection in terms of morbidity and mortality. A new approach of oral vaccination with DNA-
chitosan nanoparticles appears interesting because of their great stability and the ease of target accessibility, besides chitosan
immunostimulatory properties. Here we described that chitosan nanoparticles loaded with plasmid DNA encoding Rho1-GTPase
protein of Schistosoma mansoni, prepared at diﬀerent molar ratios of primary amines to DNA phosphate anion (N/P), were able to
complex electrostatically with DNA and condense it into positively charged nanostructures. Nanoparticles were able to maintain
zeta potential and size characteristics in media that simulate gastric (SGF) and intestinal ﬂuids (SIF). Further in vivo studies
showed that oral immunization was not able to induce high levels of speciﬁc antibodies but induced high levels of the modulatory
cytokine IL-10. This resulted in a signiﬁcative reduce of liver pathology, although it could not protect mice of infection challenge
withS. mansoni worms. Mice immunized only with chitosan nanoparticles presented 47% of protection against parasite infection,
suggesting an important role of chitosan in inducing a protective immune response against schistosomiasis, which will be more
explored in further studies.
1.Introduction
Schistosomiasis is an important parasitic disease, caused
by trematode worms of the genus Schistosoma, aﬀecting
more than 207 million people worldwide, with a further 700
million individuals living at risk of infection [1] and it causes
upto250,000deathsperyear[2].Furthermore,theimpactof
the severe and debilitating eﬀects of schistosomiasis accounts
for the loss of 4.5 million disability adjusted life years
(DALYs) annually [3].
Currently, schistosomiasis control strategies are predom-
inantly based on the treatment of infected individuals with
safe and eﬀective drugs [4]. However, mass treatment has
been proven to be insuﬃcient to stop disease transmission,
prevent reinfection, or reduce parasite-induced illness [5, 6].
Therefore a great eﬀort to develop a protective vaccine to
be used in combination with chemotherapy and improved
sanitation in order to curb the menace of schistosomiasis is
required.
Desirable characteristics of a schistosomiasis vaccine
candidate include not only the capacity to reduce worm
burden and fecundity but also the capacity to downregulate
granulomatous responses to eggs that become trapped in the
host liver and intestines and cause morbidity [7]. A vaccine
that induces even a partial reduction in worm burdens could
considerably reduce pathology and limit parasite trans-
mission [8].2 The Scientiﬁc World Journal
The identiﬁcation of a speciﬁc antigen is a crucial task in
the development of an eﬀective vaccine. However, the anti-
gens tested until now were found to induce insuﬃcient levels
of protection during the preclinical studies [9], what makes
necessary the search for new antigens. In schistosomiasis,
thereisevidenceindicatingtheinvolvementoflowmolecular
weight proteins that bind to GTP in the process of matu-
ration and deposition of eggs by the females of S. mansoni
[10]. Therefore, the protein Rho1-GTPase of S. mansoni is
probably related with the pathological response caused by
parasites [11] and this brings an interest in understanding
the role of this protein in immunological processes resulting
from schistosomiasis and on the evaluation of its potential as
a vaccine candidate.
Despite current challenges to improve delivery and
immunogenicity, DNA vaccination has several major advan-
tages over traditional vaccines or over other types of inves-
tigational vaccine platforms [12]. DNA vaccine technology
is a simple concept based on relatively simple design and
production technologies [13]. Another advantage of DNA
vaccines over conventional protein vaccines is the low cost
of production of a highly puriﬁed product.
T od a t e ,m o s tg e n ed e l i v e r ys t r a t e g i e sh a v ec o n c e n t r a t e d
on the parenteral route of delivery and oral administration
has been largely ignored. The main advantages presented
by oral gene delivery are the ease of target accessibility and
enhancedpatientcomplianceowingtothenoninvasivedeliv-
ery method. For eﬀective oral immunization, antigens and
plasmids must be protected from the acidic and proteolytic
environment of the gastrointestinal tract, eﬃciently taken
up by cells of the gut associated lymphoid tissue (GALT),
a n da na p p r o p r i a t ei m m u n er e s p o n s em u s tb ei n d u c e d .T h e
interaction of plasmid DNA (pDNA) with a biodegradable
c a t i o n i cp o l y m e rt of o r mn a n o p a r t i c l e so ﬀers a way to
protect pDNA from degradation [14].
In this work, chitosan-based nanoparticles as adjuvant
for mucosal vaccination were chosen. Chitosan (CH) has
been considered an attractive gene carrier because it is non-
toxic and biodegradable and has mucoadhesive properties.
CHisabletoformcomplexeseasilywithDNA[15,16]which
have been shown to eﬀectively protect DNA from degrada-
tion [17]. In addition, CH has the capability to enhance the
penetration of large molecules across the mucosal surface
[14]. Finally, there has already been demonstrated CH
particle’s capability to be taken up by the Payer’s patches
[18] and its eﬀectiveness as plasmid delivery systems to
gut mucosal [19]. On the other hand, in vitro CH low
transfection eﬃciency has so far hampered its widespread
application. Therefore with the aim of improving CH
gene delivery eﬃciency, CH has been functionalized with
imidazole moieties, which acts to promote the endosomal
escape capability of CH-DNA complexes [20]. In order to
obtain higher rates of transfection, imidazole-grafted CH
was used in the present work with the aim to prepare DNA-
CH particles (encoding for Rho1-GTPase protein), for oral
administration.Besidesactingasagenecarrier,theuseofCH
to delivery DNA is even more attractive in this vaccination
strategy considering his immunostimulatory characteristics,
as has been largely described [21].
2.MaterialsandMethods
2.1. Materials
2.1.1. Imidazole-Grafted CH. Imidazole-modiﬁed CH was
prepared as previously described [20]. Brieﬂy, technical
grade CH (Chimarin, degree acetylation 13%, apparent vis-
cosity 8 mPa.s, Medicarb, Sweden) was puriﬁed by ﬁltration
of an acidic CH solution and subsequent alkali precipitation
(1M NaOH). The puriﬁed polymer was characterized by gel
permeation chromatography (GPC) and Fourier Transform-
Infrared Spectroscopy (FT-IR). The average weight molec-
ular weight of the starting material was found to be 1.2 ×
105 (GPC in 0.5M CH3COOH—0.2M CH3COONa, 25◦C).
The degree of acetylation determined by FT-IR according
to Brugnerotto et al. [22] was found to be 16%. Endo-
t o x i nl e v e l so ft h ep u r i ﬁ e dC He x t r a c t sw e r ef o u n dt ob e
lower than 0.1EU/mL, respecting the US Department of
Health and Human Services guidelines [23] for implantable
devices. Imidazole-modiﬁed CH (CHimi) was obtained by
the amidation of the glucosamine residues of CH using 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)/N-
hydroxysuccinimide (NHS) condensation system. 22% of
the primary amines of the original CH were substituted, as
determined by FT-IR.
2.1.2. Plasmid DNA. A plasmid (6176 pb), NT-GFP fusion
TOPO TA (Invitrogen), containing Rho1-GTPase (1–579)
cDNA fragment under the cytomegalovirus (CMV) early
promoter was constructed previously in our laboratory,
following the fabricant’s recommendations. The cloning was
veriﬁed by sequencing using GFP primers and conﬁrmed the
correctinsertionoftheRho1-GTPasefragmentinframewith
GFP sequence.
The plasmid was ampliﬁed in DH5α Escherichia coli
strand and isolated using the QIA-GEN Plasmid Maxi
Kit (GeneElute HP, Sigma-Aldrich). The concentration and
purity of the plasmid was accessed by spectrophotometric
analysis. The ratio between optical density at 260nm and
280nm was >1.8 and <2.0.
2.1.3. Recombinant Protein Rho1-GTPase of S. mansoni.
Rho1-GTPase was expressed as His-fusion from pET-
DEST42 (Invitrogen). The cloning was done using Gateway
System (Invitrogen) and protein expression was carried out.
The Rho1-GTPase was puriﬁed using the Ni-NTA His-Bind
aﬃnity chromatography. The His-Rho1-GTPase is hereafter
referred to as SmRho.
2.2. Preparation of CH DNA Nanoparticles. Nanoparticles
were prepared as previously described by mixing [20], while
vortexing, equal volumes of polymer solution in 5mM
acetate buﬀer pH 5.5 (0.1% (w/v)) and plasmid DNA
solution (in 25mM Na2SO4), both previously heated at 55◦C
for 10min. Complexes were allowed to form and stabilize for
15min at RT before further use. Complexes with diﬀerent
polymer:DNA molar ratios were prepared. The ratio value
(N/P molar ratio) is expressed in terms of moles of primaryThe Scientiﬁc World Journal 3
amine groups (N) of CH or CHimi to moles of DNA phos-
phate groups (P).
2.3. Characterization of Nanoparticles
2.3.1. DNA Retardation Assay. Complexes were prepared at
various N/P molar ratios as previously described; 2.5μgo f
plasmid DNA was used for the preparation of the nano-
particlesinaﬁnalvolumeof50μLand20μLofeachcomplex
solution together with 4μL of loading buﬀer (Fermentas)
was loaded in a 1% (w/v) agarose (Cambrex) gel, with
0.05μgmL−1 ethidium bromide (Q-BioGene). The elec-
trophoresis was run at 90V for 45min, using Tris-acetate-
EDTA buﬀer (pH 8) as the running buﬀer.
2.3.2. Nanoparticles Size and Zeta Potential Determination.
To characterize the size and zeta potential of the CH-
DNA complexes as prepared, these were formed at diﬀerent
N/P molar ratios as described in Section 2.2 using 10μgo f
plasmid DNA. After stabilization, complexes were diluted
to 1mL, using 5mM acetate buﬀer (pH 5.5). The zeta
potential and mean hydrodynamic size of the nanoparticles
were assessed using a Zetasizer Nano ZS (Malvern, UK).
T h eS m o l u c h o w s k im o d e lw a sa p p l i e df o rd e t e r m i n a t i o n
of the zeta potential, and cumulant analysis was used for
mean particle size determination. All measurements were
performed in triplicate at 25◦C.
To characterize the size and zeta potential of the nano-
particles when in the gastrointestinal tract conditions, the
complexes were suspended in solutions that simulate the
gastric (SGF) and intestinal ﬂuid (SIF). For this purpose,
complexes were prepared as described previously at N/P
molar ratios of 12 and 18. After stabilization, complexes were
diluted to 1mL using either SGF or SIF (described in USP
XXIV) at37◦C.After15mininthesesolutions,nanoparticles
were characterized as described previously.
2.4. Immunization Studies
2.4.1. Mice and Parasites. Six-week-old female C57BL6 mice
were purchased from the Federal University of Minas Gerais
(UFMG)animalfacility.Allprotocolsinvolvinganimalswere
approved by the local Ethics Committee on Animal Care
(CETEA-UFMG number 204/2009). Animals had free access
to food and water, with 12h light/dark cycle.
S.mansonicercariaeweremaintainedroutinelyonBiom-
phalaria glabrata snails at the Center of Research Rene Rach-
ou-Fiocuz (CPqRR). For infections, cercariae were prepared
byexposinginfectedsnailstolightfor1htoinduceshedding.
Cercariae numbers and viability were determined using a
light microscope prior to infection.
2.4.2. Treatment Groups. Five groups were submitted to dif-
ferent treatments, as follows:
Group I: control group—phosphate buﬀer saline
(PBS) (n = 5);
Group II: suspension of CH nanoparticles (n = 5)
administered by oral route;
Group III: solution of naked recombinant plasmid
DNA (50μg) administered by oral route (n = 5);
Group IV: suspension of modiﬁed CH (CHimi)—
plasmid DNA (25μg) nanoparticles administered by
oral route (n = 5);
Group V: suspension of modiﬁed CH (CHimi)—
plasmid DNA (25μg) nanoparticles administered by
intramuscular route (n = 5).
In order to evaluate the adjuvant eﬀect of CH, chitosan
nanoparticles without DNA were prepared (Group II). And
with the aim to evaluate the improvement of gene delivery
by CH modiﬁed (Chimi), Chimi-DNA nanoparticles were
administered to groups IV and V while group III received
DNA without CH. The best route of administration was also
analyzed comparing groups IV and V.
2.4.3. Immunization Schedule and Collection of Samples.
The diﬀerent formulations were administered orally with
a gavage-feeding needle (groups I–IV) and intramuscularly
with an injection in the tibialis anterior muscle (group V).
The primary immunization was followed by two immuniza-
tions with an interval of two weeks. Seven days after the last
immunization mice were challenged and then after 50 days
mice were sacriﬁced.
Blood samples were taken through tail veins from four
mice of each experimental group at two-week intervals, and
theserawerepreparedbycentrifugationandstoredat −20◦C
until further analysis. Serum was collected from immunized
and control mice to measure kinetics of speciﬁc antibodies.
2.5.MeasurementofSpeciﬁcAnti-SmRhoAntibodies. Ameas-
urement of speciﬁc anti-SmRho antibodies was per-
formed using an indirect enzyme-linked immunoabsorbent
assay (ELISA). Maxisorp 96-well microtiter plates (Nunc,
Roskilde, Denmark) were coated with 10μg/mL of SmRho
in carbonate-bicarbonate buﬀe r ,p H9 . 6 ,f o r1 6 ha t4 ◦C.
Plates were washed with a solution containing PBS 0.05%
Tween 20 (PBS-T) and were then blocked for 1h at 37◦C
with 200μL/well of PBS-casein (phosphate buﬀer saline,
pH 7.2 with 1.6% casein). Next, 100μLo fe a c hs e r u m
samplediluted1:100inPBS-casein(phosphatebuﬀersaline,
pH 7.2 with 0.25% casein) was added to each well and
was incubated for 1h at 37◦C. Plate-bound antibodies
were detected by peroxidase-conjugated anti-mouse IgG
(SIGMA), IgG1, and IgG2a (Southern Biotechnology Asso-
ciates, Inc., Birmingham, AL, USA) diluted 1:5000 in PBS
with 0.25% casein. The plates were revealed by the addition
of 100μL of detection solution (R&D systems, Minneapolis,
USA) containing tetramethylbenzidine (Thermo Scientiﬁc
Pierce) and H2O2 in each well; after 20min reactions were
stopped with the addition of 50μL of 5% (v/v) sulfuric acid
per well. The absorbance was read at 450nm in an ELISA
plate reader (ELX 800 BIO-TEK Instruments Inc.).4 The Scientiﬁc World Journal
2.6. Challenge Infection and Worm Burden Assessment. Seven
days after the last immunization, mice were challenged
through percutaneous exposure of abdominal skin to water
containing 25 cercariae (LE strain) for one hour. 50 days
after challenge, mice were sacriﬁced and adult worms were
perfused from their portal veins [24, 25]. Protection was
calculated by comparing the number of worms recovered
from each vaccinated group compared with control group
using (1):
PROTECTION (%) =
(C −I)
C

×100, (1)
where C represents the worms recovered from the saline
control group and I represents the worms recovered fromthe
experimental group.
2.7. Cytokine Analysis
2.7.1. Antigen Preparation. Antigenic preparations were ob-
tained from schistosome eggs (SEA) and adult worms
(SWAP), prepared as soluble supernatant ﬂuids from buf-
fered saline homogenates of the respective life-cycle stages
[26]. Cytokine production was evaluated when splenocytes
were stimulated with rSmRho, SWAP, or SEA.
2.7.2. Cytokine Experiment. Cytokine experiments were per-
formed using splenocyte cultures from individual mice of
control and experimental groups. Splenocytes were isolated
from macerated spleens of individual mice at day 50 post
infection. Cells were washed twice with sterile PBS and were
plated at a concentration of 1 × 106 cells per well in RPMI
1640 medium (Gibco, Carlsbad, CA, USA) supplemented
with 10% FBS, 100U/mL of penicillin G sodium, 100μg/mL
of streptomycin sulfate, and 250ng/mL of amphotericin B.
Splenocytes were maintained in culture with medium alone
or stimulated with SmRho (25μg/mL), SWAP (25μg/mL),
or SEA (25μg/mL). The 96-well plates (Nunc, Denmark)
were maintained in an incubator at 37◦Cw i t h5 %C O 2.
Culture supernatants were collected after 72h for IL-10, IL-
4, TGF-β,a n dI F N - γ analysis. IL-4, IL-10, IFN-γ,a n dT G F - β
concentrationsweremeasuredusingDuosetELISAkit(R&D
Systems, USA) according to the manufacturer’s instructions.
2.8. Hepatic Granuloma Analysis. Liver fragments from mice
(3 mice per group) of control and experimental groups
immunized and infected were collected 50 days post in-
fection in order to evaluate the eﬀect of immunization
on granuloma formation. Liver fragments were ﬁxed in
10% paraformaldehyde. Fragments processed for paraﬃn
embedding and histopathological sections were cut using a
microtome at 5μm. Sections were stained on a slide with
hematoxylin-eosin(HE).Theareasofindividualgranulomas
were obtained through the MacBiophotonics ImageJ soft-
ware analyzer. Fifteen granulomas from each mouse with
a single well-deﬁned egg were randomly chosen using a
microscope with the 4x objective lens; granulomas were
then scanned using JVC TK-1270/RGB microcamera. Using
M    DNA    0.5       1         2    3         6        12       18       24
(a)
M     DNA  0.5       1         2     3         6       12       18      24
(b)
Figure 1: Electrophoretic retention of DNA by CH (a) and CHimi
(b). Unless otherwise mentioned, lanes assignments correspond to
N/P molar ratios tested and are as follows: Lane M: gene ruler 1kb
DNA ladder; lane DNA: plasmid DNA solution; lane 0.5–24: N/P
molar ratios.
a digital pad, the total area of each granuloma was measured,
and the results were expressed in square micrometers (μm2).
2.9. Statistical Analysis. Statistical analysis was performed
using the ANOVA test and the GraphPad Prism 5 software
package.TheBonferronitestwasusedtocomparesubgroups
with the level of signiﬁcance set at P<0.05.
3. Results
3.1. Nanoparticles Characterization. To determine the min-
imum amount of CHimi polymer required to complex
plasmid DNA fully, varying amounts of polymer were
mixed with DNA solutions with a ﬁxed amount of plasmid
DNA, and the resulting complexes were evaluated for their
electrophoretic mobility. The modiﬁed polymers halt DNA
mobilityatthesameN/PmolarratioasfornonmodiﬁedCH,
which was found to be 2 (Figure 1).
The size of CH-DNA nanoparticles was determined by
lightscattering.ParticleswithN/Pmolarratiosragingfrom1
to24wereevaluatedandresultspresentedonFigure 2(a).For
N/P molar ratios higher than 3, nanoparticles with a mean
particle size around 300nm were obtained independently of
the polymer used. For lower N/P molar ratios, the size of the
particles was around 500–600nm.
Nanoparticles were also characterized in terms of zeta
potential (Figure 2(b)). In both cases, zeta potential determi-
nations have shown that an excess of polymer (N/P molarThe Scientiﬁc World Journal 5
0
250
500
750
1000
S
i
z
e
 
(
n
m
)
0 2 4 6 8 10 12 14 16 18 20 22 24
N/P molar ratio
CH-DNA
CHimi-DNA
(a)
2 4 6 8 1 01 21 41 61 82 02 224
−50
−40
−30
−20
−10
0
10
20
N/P molar ratio
CH-DNA
CHimi-DNA
ζ
p
o
t
e
n
t
i
a
l
 
(
m
V
)
(b)
Figure 2: Mean particle size (a) and zeta potential (b) of CH-
based complexes as a function of N/P molar ratio (measurements
performed at 25◦C, pH 5.5; average ± SD, n = 3).
ratio >2) allowed the assembly of particles with a positive
global net charge that stabilizes at a value between +16mV
and +20mV, which is in agreement with the values found in
the literature for complexes based on CH [17].
3.1.1. Resistance of CH-DNA Nanoparticles to the Inﬂuence of
pH and Temperature. In order to evaluate the nanoparticles
prepared as a candidate to oral delivery system for DNA
vaccines, the stability of CH-DNA complexes in media that
simulatesthestomachandintestinalenvironmentwastested.
For this propose size and zeta potential of the particles
suspended in SGF pH = 1.2 or SIF pH = 6.8, both at 37◦C,
were measured using nanoparticles with N/P molar ratios of
12 and 18. The results illustrated in Figure 3 show that the
complexes were very stable at 37◦C suspended in diﬀerent
buﬀers during the period of incubation. Small variations on
size were observed but the range continues between 200 and
300nm. On the other side, as predictable, the increase of
the zeta potential to values near +25mV is explained by
the higher protonation degree of the CH amine groups in
acidicenvironment.Conversely,thecontactwithahigherpH
solution resulted in the decrease of the zeta potential of the
nanoparticles.
3.2. Antibody Proﬁle following Mice Immunization. Further
in vivo studies were performed to investigate the potential
utility of oral nanoparticle-mediated gene immunization in
eliciting the production of antibodies or modulating the
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Figure 3: Zeta potential (a) and mean size (b) of CH-based
complexes prepared in N/P molar ratios (R) 12 and 18 at diﬀerent
media. The measures were realized at 25◦Ci na c e t a t eb u ﬀer pH 5.5
and at a 37◦C in SGF and SIF.
immune response. To evaluate the levels of rSmRho-speciﬁc
IgG antibodies serum samples from vaccinated animals from
each group were tested by ELISA. The measures of IgG
antibodies showed that nanoparticles were able to induce
the production of speciﬁc rSmRho antibodies, even in
small amounts. Signiﬁcant levels of IgG antibodies could
be veriﬁed in the serum collected from DNA-, CHimi-
DNA-, and CHimi-DNA- (i.m.-) immunized groups, in
determined times during the immunization or after the
challengeinfection(Figure 4).Althoughtheselevelswerenot
sustained for long periods, it shows that the transfection was
eﬀective and allowed SmRho transcription by the DNA and
CHimi-DNA nanoparticles.
3.3. Protective Eﬀect of CH-DNA Nanoparticles Vaccination.
To investigate the protective activity induced by vaccination6 The Scientiﬁc World Journal
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Figure 4: Serum anti-rSmRho-speciﬁc IgG levels of mice immunized orally with DNA (a) or CHimi-DNA (b) and intramusculary with
CHimi-DNA nanoparticles (c). Sera of immunized mice were collected at days 15 (one week after the ﬁrst immunization), 30, 45, 60, 75,
and 95 and assayed by ELISA. The results are presented as the mean absorbance measured at 450nm for each group. Statistically signiﬁcant
diﬀerences of vaccinated mice compared with the control group, PBS, in each time evaluated, are indicated by (∗)f o rP<0.05.
with CH and CHimi-DNA nanoparticles in murine model
of S. mansoni infection, immunized mice were challenged
with 25 cercariae. The diﬀerence in the number of adult
worms recovered in the experimental groups compared
t oc o n t r o lg r o u pw a sc a l c u l a t e d5 0d a y sp o s tc h a l l e n g e
(Table 1). Only the group of animals immunized with CH
nanoparticles without DNA and challenged with cercariae
showedasigniﬁcantreductionof47%inadultwormburden,
compared with the saline control group (mice received PBS)
in (Table 1). This result suggests that CH has an important
role in inducing protection against S. mansoni infection, and
that the plasmid DNA, which codiﬁes the SmRho protein,
in this experiment, did not have a huge contribution in
reducing worm burden. The later can be related to a lower
rate of transfection and therefore the amount of protein
expressed was not suﬃcient to give rise protective activity.
3.4. rSmRho Vaccination-Induced Granuloma Downmodu-
lation. To evaluate the eﬀect of the proposed vaccine on
reducing granuloma reactions, histological analysis was per-
formed by digital morphometry. Seven days after the third
immunization, mice were challenged with 25 cercariae. After
50 days of challenge infection, mice were sacriﬁced and liver
samples were taken for histological analysis. Hematoxylin
andeosinstainedliversectionswerethenusedtomeasurethe
size of individual granulomas. CHimi-DNA nanoparticles
vaccination by oral route reduced liver granuloma area by
37,0% (Table 1), compared with mice that were immunized
with PBS (Table 1). Smaller granulomas were also observed
in mice immunized with DNA without nanoparticles, with
24,9% of granuloma area reduction (Table 1). However these
granulomas were not as small as those observed in the
CHimi-DNA immunized groups. These ﬁndings suggest that
the antigen codiﬁed by the plasmid DNA was importantThe Scientiﬁc World Journal 7
Table 1: Protective eﬀect and liver granuloma size induced by C57BL/6 mice vaccination with CH-DNA nanoparticles and challenged with
25 S. mansoni cercariae.
Groups Total worms mean ± SD Percentage reduction
of worm burden
Hepatic granuloma area
(μm2) Mean ± SD
Percentage reduction
of granuloma area
Control 19.0 ± 2.4 — 109743 ± 47427 —
CH 10.1 ± 0.81∗ 47∗ 83269 ± 50226 24,1
DNA 13.8 ± 4.5 27 82352 ± 46222∗ 24,9∗
CHimi-DNA 16.5 ± 3.6 23 69085 ± 40416∗ 37,0∗
Chimi-DNA (i.m.) 17.5 ± 4.1 8 108222 ± 50046 1,39
∗Statistically signiﬁcant compared with the control group (P<0.05).
to induce this antipathological eﬀect, and the better result
observed in mice immunized CHimi-DNA nanoparticles is
probably referred to the higher rate of transfection mediated
by the modiﬁed CH (CHimi) compared with the group
immunized with naked DNA.
3.5. Cytokine Proﬁles Induced by rSmRho Immunization.
Cytokine experiments were performed using splenocyte cul-
tures from individual mice immunized with CHimi-DNA
nanoparticles. Production (IFN-γ, IL-4, IL-10, and TGF-β)
was measured in the supernatants of spleen cells cultured
only in RPMI medium containing fetal bovine serum
or in the presence of rSmRho, SWAP, or SEA. Higher
levels of the immunomodulatory cytokine IL-10 were pro-
duced by rSmRho-stimulated splenocytes from CHimi-
DNA-immunized group by intramuscular route and also
from Chimi-DNA group immunized by oral route, com-
pared with the control-stimulated splenocytes. Besides that,
splenocytes from mice immunized with CH nanoparticles
and stimulated with rSmRho showed a signiﬁcative pro-
duction of IL-10, although their levels were not so high
compared with CHimi-DNA immunized groups (Figure 5
(A)). No signiﬁcative levels of IFN-γ, a cytokine typical of
Th1-type immune response, were produced by rSmRho-
stimulated splenocytes from immunized groups, but when
splenocytes from these groups were stimulated with SWAP,
there were measured higher levels compared with the
control-stimulated splenocytes (Figure 5 (B)). Over again no
signiﬁcant secretion of IL-4, a Th2 cytokine, was produced
by rSmRho-stimulated splenocytes compared to control-
stimulated splenocytes, but there was a considerable produc-
tion of IL-4 when splenocytes of immunized groups were
stimulated with SEA, what is a typical cytokine of granulo-
matous reaction (Figure 5 (C)). No signiﬁcant diﬀerence on
TGF-β production was detected between rSmRho, SWAP, or
SEA-stimulated splenocytes from immunized groups (data
not shown). These results indicate that the immunization of
mice with those formulations of CHimi-DNA nanoparticles
didnotinduceapredominantTh1orTh2immuneresponse,
but it induced mainly high levels of the immunomodulatory
cytokine IL-10.
4. Discussion
Schistosomiasis is a chronic debilitating parasitic disease that
represents a major health problem in endemic areas, such
as various parts of South America, Africa, and Southeast
Asia [27]. Since current schistosomiasis control programs
applied to reduce morbidity and mortality have been proven
inadequate and many commonly employed measures have
been ineﬀective, there is a consensus that the development
of an appropriate protective vaccine would be a crucial part
of the overall integrated control strategy.
Inthepresentstudy,wefoundthatitispossibletoinduce
some arms of a protective immunity against experimental
schistosomiasisinmiceusingCHandCHimi-DNAnanopar-
ticles administered by oral route. This vaccination strategy
oﬀersmanytechnicaladvantages,includingasimpleproduc-
tionprocessandthepossibilityofadministrationwithoutthe
need of the use of needles, which facilitates administration
mainly in development areas [28]. Additionally, polymeric
carriers are potentially advantageous over viral vectors,
which have in vivo limitations including wild type reversion
and immunogenicity. The use of cationic lipids in vivo is
also hindered by its toxicity, complement activation, and
liver tropism. CH has been an attractive gene carrier because
it is one of the few polycations of natural origin available
and may be superior to other vectors including liposomes
due to its minimal toxicity [29]. CH–DNA nanoparticles are
spontaneously formed by the complex coacervation method
using sodium sulphate as desolvating agent [17]. However,
the eﬃcacy presented by CH-based vectors is insuﬃcient
[30]. Moreira et al. [20] demonstrated that the introduction
of imidazole moieties into the CH backbone leads to an
improvement of its buﬀering capacity and promotes the
endosomal escape capability of CH-DNA complexes via
membrane destabilization of the acidiﬁed endosomes. It
resultedinincreasingthechancesofreachingthenucleusand
mediatedasuccessfuldeliveryofthetransgene.Inthepresent
study, this modiﬁed CH (CHimi) was used with the aim of
improving CH transfection eﬃciency. The characterization
of nanoparticles showed that CH modiﬁed did not interfere
with the basic properties of CH as described by Moreira et al.
[20].
Electrophoretic retention of DNA was assessed for com-
plexes prepared with increasing amounts of polymer. The
modiﬁedpolymerhaltsDNAmobilityatthesameN/Pmolar
ratio (primary amines to plasmid DNA phosphate groups
ratio) as nonmodiﬁed CH, which was found to be 2. Upon
proving the ability of the modiﬁed polymers to complex
DNA, it was important to evaluate their size and charge. For
N/P molar ratios >3, no diﬀerences were observed in the8 The Scientiﬁc World Journal
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Figure 5: Cytokine proﬁles of mice immunized with CH-DNA nanoparticles. Splenocytes isolated from mice immunized with Chimi-DNA
nanoparticles (a), CHimi-DNA (i.m.) (b), DNA (c), or CH (d) were assayed as IL-10 (A), IL-4 (B) and INF-γ (C), production in response to
in vitro stimulation with SWAP (25μg/mL), rSmRho (25μg/mL), SEA (25μg/mL), or medium alone as control. Results represent the mean
± SD of each group. ∗Statistically signiﬁcant diﬀerences between cytokines produced after SWAP, rSmRho, or SEA stimulation compared
with unstimulated splenocytes (control) (P<0.05).
behaviorofCHimi-DNAorCH-DNAnanoparticlesinterms
of mean particle size and zeta potential. Large particles and
polydisperse populations were observed only at lower N/P
molar ratios. Other authors have also reported increased size
at molar ratio 1 (the condition at which the zeta potential
of the complexes is close to neutrality), which could be
explained by the instability of the colloidal system. The
dimension range referred to in the literature for CH-based
complexes with DNA is quite wide and found to be strongly
dependent on preparation conditions [17]. For particles
preparedbythecoacervationmethod,thesizerangereported
was between 150 and 500nm [17]. The results obtained with
the present systems are therefore in close agreement with
these ﬁndings. Besides that, complex size has an important
role in uptake by cells. Smaller complexes have the advantage
of entering in cells by endocytosis and/or pinocytosis, which
favors, therefore, the eﬃciency of transfection [30]. In
addition, the charge is also important to promote the uptake
by cells, since many authors believe that particles charged
positively favor their interactions with the cell membrane
what facilitates their entrance in cells [31, 32].
To evaluate the behavior of these nanoparticles in media
at diﬀerent pHs and at physiological temperature, DNA-CH
complexes were prepared at the N/P molar ratio of 12 and
18 and submitted to SGF pH = 1.2 and SIF pH = 6.8t o
measure their size and zeta potential. The results showed
that nanoparticles were resistant to pH media of SGF and
SIF at 37◦C. Complexes prepared with both CH and CHimi
presented similar behavior, with little alterations in their size
and zeta potential. To the best of our knowledge, this is
the ﬁrst time that such study has been conducted, showing
that these nanoparticles will resist degradation during their
passage in the gastrointestinal tract, what is desirable in oral
immunizations.
After characterization, the immunization with nanopar-
ticles was realized to investigate the eﬀect of CH-DNA
nanoparticles by oral delivery on immune response in
mice and their potential to treat the immunopathological
responses or prevent infection.
Our results demonstrated that the antipathological
response induced against infection with cercariae is probably
not related to the antibodies against rSmRho, because the
assessment to the antibodies production by immunized mice
showed low levels of rSmRho speciﬁc antibodies, although
theselevelshadbeensigniﬁcativeatdeterminedtimesduring
the period evaluated. On the other hand, the groups that10 The Scientiﬁc World Journal
showed the higher reduction in granuloma areas, CHimi-
DNA (37%) and DNA (24.9%), were groups in which
the formulation administered carried the plasmid DNA
that codiﬁes the SmRho protein. According to this, studies
realized by other authors had suggested the involvement of
this protein in process of maturation and egg deposition
by S. mansoni females [10]. Besides that, Chen and Bennett
[33] have related that the impairment of Rho1-GTPase
synthesis can reduce egg production in vitro and in vivo by
S. mansoni females, and therefore, it blocks the pathological
eﬀects of the disease in mice infected. These facts revealed
an antipathological role of SmRho, but more studies are
required to obtain a better understanding of the involvement
of this protein in the process of infection of S. mansoni.
The modulation of immunopathological responses of S.
mansoni infection induced by SmRho is possibly related to
the high levels of the regulatory cytokine IL-10 detected in
splenocytes stimulation
with rSmRho and also with SEA-stimulation. IL-10 plays
a key regulatory role in facilitating the shift from a Th1
to Th2 response and preventing the development of severe
pathologyduetoexcessiveTh1and/orTh2responses[34].In
the early stages of the granulomatous response, IL-10 acts to
suppress the production of Th1 cytokines such as IFN-γ [35,
36], possibly by regulating IL-12/IL-12R expression which,
in turn, modulates IFN-γ expression [37]. Hoﬀmann et al.
[38] have also demonstrated that IL-10 is essential to prevent
excessive Th2 responses in IL-10 knockout mice. It was the
proﬁle observed after DNA-nanoparticles immunization.
To determine whether CHimi-DNA nanoparticles con-
ferred protection against S. mansoni infection, immunized
mice were challenged with cercariae and worm burdens were
assessed.Thehigherpercentageofreductioninwormburden
was observed in mice immunized with CH nanoparticles
without DNA, which was found to be 47%. Groups immu-
nized with DNA or CHimi-DNA nanoparticles presented
a considerable percentage of protection, which was 27%
and 23%, respectively. The larger protection induced by
CH suggests that it has an important role in stimulating
the immune system and inducing a protective immune
response against schistosomiasis. In fact, some authors have
demonstrated that the major humoral immune responses
in animals infected with S. mansoni are directed toward
carbohydrate antigens. Among these antigens are complex-
type N-glycans expressing LDN [GalNAcbeta1-4GlcNAc-R],
LDNF [GalNAcbeta1-4(Fucalpha1-3)GlcNAc-R], and poly-
meric Lewis x (Lex) [Galbeta1-4(Fucalpha1-3)GlcNAc] n-R
epitopes [39]. All these antigens have in common a structure
of GlcNAc (N-Acetylglucosamine), and this monosaccharide
is the monomeric unit of the polymer chitin, from which the
CH derives from. Therefore, it could be suggested that the
antibodies produced against the structure of CH can cross-
react with these antigens present in the surface of parasites,
and they have a role in conferring protection. Additionally,
Nyame and coworkers [39] showed that monoclonal anti-
bodies to LDN in the presence of complement eﬃciently kill
schistosomula in vitro, what can be related in reduction of
worm burden. However, to conﬁrm this hypothesis further
investigations are required.
The lower rate of protection obtained by CHimi-DNA
group can be explained by the number of CH nanoparticles
in the formulation to be much less than the CH immunized
group and also because the modiﬁed CH has a structure not
so similar with the polysaccharides present in schistosoma
tegument.
Thus, we showed that the candidate of vaccine based on
CHimi-DNA nanoparticles is able to modulate the granu-
loma area, which represents the major pathological response
in schistosomiasis, and therefore, it can be useful in pre-
venting or reducing such injuries of the disease, mainly in
underdevelopedcountries.Furthermore,theresultsobtained
from these works, although being preliminaries data, suggest
an important role of CH in inducing protection against
infection of S. mansoni. Finally, we proposed that it is
possible to merge both eﬀects previously mentioned in an
appropriate antischistosomiasis vaccine where the Chimi-
DNA nanoparticles would be joined to CH nanoparticles,
with the aim to obtain an eﬀective protection and a reduced
pathology in a single immunized group.
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